The global chromosomal phasing non-invasive prenatal testing (NIPT) market is experiencing a profound paradigm shift. As clinical genetics transitions from basic aneuploidy screening toward comprehensive inherited risk assessment, chromosomal phasing technologies are emerging as essential tools in modern obstetrics. According to market research from Fact.MR, the market is projected to expand from USD 639.6 million in 2026 to USD 1,270.0 million by 2036, representing a steady compound annual growth rate (CAGR) of 7.1% over the ten-year forecast period.

Having surpassed USD 597.2 million in 2025, the market is set to generate an absolute dollar opportunity of USD 630.4 million through 2036. This sustained expansion reflects the accelerating adoption of parental haplotyping, broader commercial availability of single-gene NIPT panels, and escalating demand for non-invasive fetal risk evaluation when carrier screening identifies parental genetic mutations.

Get a Sample Copy of the Chromosomal Phasing NIPT Market Report

Key Market Highlights at a Glance

• 2025 Market Valuation: USD 597.2 million

• 2026 Market Valuation: USD 639.6 million

• 2036 Forecast Valuation: USD 1,270.0 million

• Forecast Period: 2026–2036

• Growth Rate: 7.1% CAGR

• Absolute Dollar Opportunity: USD 630.4 million

• Leading Test Type Segment: Single-Gene NIPT (30.0% share in 2026)

• Leading Technology Segment: Parental Haplotyping (30.0% share in 2026)

• Leading Indication Segment: Monogenic Disorders (30.0% share in 2026)

• Leading End-User Segment: Hospitals (30.0% share in 2026)

• Fastest-Growing Country: Germany (9.6% CAGR)

Why Is the Chromosomal Phasing NIPT Market Accelerating?

Traditional non-invasive prenatal screening primarily targets common numerical chromosomal abnormalities such as trisomies 21, 18, and 13. However, chromosomal phasing enables clinicians to distinguish maternal and paternal haplotypes within cell-free fetal DNA (cfDNA). This breakthrough allows for accurate non-invasive determination of whether a fetus has inherited a disease-causing genetic variant from carrier parents.

Primary Industry Growth Drivers

1. Integration with Carrier Screening: Increased pre-conception and early-pregnancy carrier screening identifies at-risk couples who require precise fetal risk mapping.

2. Reduction of Invasive Procedures: Parental haplotyping reduces reliance on chorionic villus sampling (CVS) or amniocentesis for monogenic disorder screening.

3. Advanced Bioinformatics: Improved algorithms, high-throughput sequencing, and molecular counting platforms have reduced no-call rates and increased assay sensitivity.

"Chromosomal phasing is helping prenatal testing move beyond common chromosome screening toward more personalized inherited-disease assessment. Market success will depend on reliable fetal DNA thresholds, fewer failed tests, strong parental-genetics interpretation, and clear communication distinguishing screening results from confirmed diagnoses."

— Shambhu Nath Jha, Senior Analyst at Fact.MR

Segmental Breakdown and Market Dominance

Single-Gene NIPT Leads Test Types (30.0% Market Share)

Single-gene NIPT is projected to account for 30.0% of overall market demand in 2026. This dominant share stems from its targeted utility in pregnancies with known familial risks or positive carrier screen findings, providing clear diagnostic answers without unnecessary broad-spectrum analysis.

Parental Haplotyping Commands Technology Landscape (30.0% Share)

Parental haplotyping is forecast to represent 30.0% of total technology market share in 2026. By establishing parental genetic haplotypes, this approach allows laboratories to track fetal inheritance patterns across cell-free DNA fragments, making it the preferred technological framework for evaluating inherited monogenic conditions.

Monogenic Disorders Drive Clinical Applications (30.0% Share)

Addressing specific single-gene mutations, monogenic disorder testing will hold 30.0% of market demand in 2026. This focus extends NIPT beyond general chromosomal screening into actionable diagnostic workflows for cystic fibrosis, spinal muscular atrophy, and sickle cell anemia.

Hospitals Remain the Core End User (30.0% Share)

Hospitals will maintain a 30.0% market share in 2026, serving as the central delivery point for integrated prenatal care. Complex genetic screening relies heavily on hospital networks where maternal-fetal medicine specialists and certified genetic counselors coordinate patient management.

Unlock Direct Access to the Full Chromosomal Phasing NIPT Market Report

Regional Performance and Country Growth Rates

Germany leads global growth with a 9.6% CAGR, supported by robust clinical governance and seamless links between screening, counseling, and confirmatory diagnostics. Meanwhile, the United States continues to drive technological innovation through leading diagnostic developers and extensive clinical trials.

Competitive Landscape and Key Players

Key industry players include Natera, Inc., BillionToOne, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., BGI Genomics Co., Ltd., Laboratory Corporation of America Holdings (Labcorp), and Quest Diagnostics Incorporated. Competition is shifting from pure sequencing throughput toward bioinformatic precision, clinical validation, transparent fetal-fraction reporting, and comprehensive genetic counseling support.

Explore Comprehensive Industry Trends in the Full NIPT Market Report

Browse Related Market Intelligence Reports in Healthcare